Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07148739 · ClinicalTrials.gov registry record · Phase 4

Ensuring Access to Optimal Therapy in CF: The ENACT Study

A Phase 4 study of Cystic Fibrosis (CF), sponsored by Arkansas Children's Hospital Research Institute.

Recruiting
Registry status
Phase 4
Development phase
95
Enrollment target
2
Study locations

NCT07148739: Recruiting Phase 4 study of Cystic Fibrosis (CF), sponsored by Arkansas Children's Hospital Research Institute.

NCT07148739 is a Phase 4 study of Cystic Fibrosis (CF) that is actively recruiting participants, run by Arkansas Children's Hospital Research Institute. The registered enrollment target is 95 participants, below the 134-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (29% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07148739, a Phase 4 study of Cystic Fibrosis (CF), is actively recruiting participants, sponsored by Arkansas Children's Hospital Research Institute.

RECRUITING
Registry status
Phase 4
Development phase
95 participants
Enrollment target
2
Study locations

Study Summary

This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).

Primary Outcome

Drug concentration of CFTR modulators

Conditions Studied

Interventions

  • DRUG Elexacaftor / Ivacaftor / Tezacaftor
  • OTHER therapeutic drug monitoring

Study Locations (2)

Arkansas

  • Arkansas Children's Hospital - Little Rock

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 95 participants
Start Date 2025-06-10
Est. Completion 2030-12
Phase Phase 4

What NCT07148739 shows while recruiting

NCT07148739 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 134-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (29% lower).

The record links to 1 condition, with Cystic Fibrosis (CF) appearing as the primary indexed condition, and to 2 interventions - of which Elexacaftor / Ivacaftor / Tezacaftor is the first listed.

NCT07148739 reports a single indexed study location in Arkansas, Washington.

Frequently Asked Questions

What is clinical trial NCT07148739 about?

NCT07148739 is a clinical study titled "Ensuring Access to Optimal Therapy in CF: The ENACT Study". This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing the...

What is the current status of trial NCT07148739?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 95 participants. The study started on 2025-06-10. Estimated completion is 2030-12.

What conditions does trial NCT07148739 study?

This clinical trial studies the following conditions: Cystic Fibrosis (CF).

What interventions are being tested in trial NCT07148739?

The interventions under investigation include: Elexacaftor / Ivacaftor / Tezacaftor (DRUG), therapeutic drug monitoring (OTHER).

Who is sponsoring clinical trial NCT07148739?

This trial is sponsored by Arkansas Children's Hospital Research Institute, which has 97 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07148739 being conducted?

This trial has 2 study locations across Arkansas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis (CF)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07148739's enrollment target sits among peer trials

95 6th of 14 higher than 9 of 14 other Cystic Fibrosis (CF) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis (CF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03339128 · 95 participants · Phase 2

    Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

  • NCT03509961 · 95 participants · Phase 2

    The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • NCT03694756 · 95 participants · NA

    TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer

  • NCT04206215 · 95 participants · NA

    Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07148739, the US trial registry maintained by the National Library of Medicine. NCT07148739 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.